

Anders Nykjaer, et al.

U.S. Serial No.: 10/539,443; Filed: June 20, 2005

Amendment in Response to Final Office Action submitted March 23, 2010

Page 2

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-90. (Canceled)

Claim 91. (Previously presented) The method of claim 93, wherein the receptor is exposed to the antibody in an amount of from 1 μ g/kg to about 100 mg/kg per day.

Claim 92. (Canceled)

Claim 93. (Currently amended) A method for inhibiting the binding of a pro-neurotrophin pro-NGF to a sortilin receptor of the Vps10p-domain receptor family in an animal, wherein the animal suffers from an injury or dysfunction of the central or peripheral nervous system in need of increased survival of neurons, which comprises exposing said receptor to an inhibitorily effective amount of an antibody which binds to an extracellular part of such [[a]] receptor, and thereby inhibits the binding of a pro-neurotrophin pro-NGF to said receptor.

Claim 94. (Previously presented) The method of claim 93, wherein the animal is a human being.

Claims 95-96. (Canceled)

Claim 97. (Previously presented) The method of claim 93, wherein the antibody binds to a peptide comprising amino acid residues 612-740 of SEQ ID NO:1.

Anders Nykjaer, et al.

U.S. Serial No.: 10/539,443; Filed: June 20, 2005

Amendment in Response to Final Office Action submitted March 23, 2010

Page 3

Claim 98.(Previously presented)The method of claim 93, wherein the antibody binds to a peptide comprising amino acid residues 24-77 of SEQ ID NO:1.

Claims 99-100.(Canceled)